BCOP Updates 2024: Prevention and Treatment of Cancer-Associated Thrombosis

Type: Individual•Format: On-demand

Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. There have been several recent studies comparing direct oral anticoagulants (DOACs) with low-molecular weight heparin (LMWH) in the management of CAT. This session will discuss recent updates to guidelines for the prevention and management of CAT and will review data comparing the efficacy and safety of DOACs versus LMWH in the treatment of CAT.

BCOP Updates 2024:  Prevention and Treatment of Cancer-Associated Thrombosis

Author: Andy Maldonado, PharmD, BCOP

UAN#: 0465-0000-24-088-H01-P

Learning Objectives:

  1. Identify patients with cancer who may benefit from primary thromboprophylaxis.
  2. Compare data for use of direct oral anticoagulants (DOACs) versus low-molecular weight heparin (LMWH) in the treatment of cancer-associated thrombosis (CAT).
  3. Select the most appropriate anticoagulant for treatment of CAT given patient-specific characteristics.
  4. Discuss duration of treatment for CAT.

Get it Now!

Knowledge Course for Pharmacist

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.